logo
logo

Novasenta Completes $40 Million Series A To Advance Novel Cancer Therapeutics

Novasenta Completes $40 Million Series A To Advance Novel Cancer Therapeutics

07/29/22, 12:05 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgpittsburgh
Money raised
$40 million
Industry
biotechnology
Round Type
series a
Novasenta Inc., a startup biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, today announced the completion of $40 million in Series A financing led by UPMC Enterprises, the innovation, venture capital and commercialization arm of leading health system UPMC. The funding will allow Novasenta to advance its pipeline of antibody-based therapeutics and expand its proprietary computational platforms for target discovery, while continuing to recruit top talent.

Company Info

Company
Novasenta Inc.
Location
350 technology drive
pittsburgh, pennsylvania, united states
Additional Info
Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer. We use systematic, rigorous, and unbiased human tumor microenvironment analysis to uncover new druggable targets, exploiting the critical interplay of disease, immune response, and metabolism. Single-cell level analysis of high-quality, human tumor samples combined with the advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient. Our goal is to identify novel targets to generate effective therapies for a range of cancers.

Related People